CO-1686
Total Payments
$16,646
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $16,646 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16,646 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy (EGFR) | Clovis Oncology, Inc. | $16,646 | 0 |
Top Doctors Receiving Payments for CO-1686
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Madison, WI | $16,646 | 2 |
Ad
Manufacturing Companies
- Clovis Oncology, Inc. $16,646
Product Information
- Type Drug
- Total Payments $16,646
- Total Doctors 0
- Transactions 2
About CO-1686
CO-1686 is a drug associated with $16,646 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Clovis Oncology, Inc..
Payment data is available from 2020 to 2020. In 2020, $16,646 was paid across 2 transactions to 0 doctors.
The most common payment nature for CO-1686 is "Unspecified" ($16,646, 100.0% of total).
CO-1686 is associated with 1 research study, including "TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy (EGFR)" ($16,646).